HUP9903771A3 - Targeted cytotoxic anthracycline analogs - Google Patents

Targeted cytotoxic anthracycline analogs

Info

Publication number
HUP9903771A3
HUP9903771A3 HU9903771A HUP9903771A HUP9903771A3 HU P9903771 A3 HUP9903771 A3 HU P9903771A3 HU 9903771 A HU9903771 A HU 9903771A HU P9903771 A HUP9903771 A HU P9903771A HU P9903771 A3 HUP9903771 A3 HU P9903771A3
Authority
HU
Hungary
Prior art keywords
targeted cytotoxic
anthracycline analogs
cytotoxic anthracycline
analogs
targeted
Prior art date
Application number
HU9903771A
Other languages
English (en)
Original Assignee
Univ Tulane
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24247176&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP9903771(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Tulane filed Critical Univ Tulane
Publication of HUP9903771A2 publication Critical patent/HUP9903771A2/hu
Publication of HUP9903771A3 publication Critical patent/HUP9903771A3/hu
Publication of HU229870B1 publication Critical patent/HU229870B1/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HU9903771A 1995-11-27 1996-11-14 Targeted cytotoxic anthracycline analogs HU229870B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/562,652 US5843903A (en) 1995-11-27 1995-11-27 Targeted cytotoxic anthracycline analogs
PCT/EP1996/005029 WO1997019954A1 (en) 1995-11-27 1996-11-14 Targeted cytotoxic anthracycline analogs

Publications (3)

Publication Number Publication Date
HUP9903771A2 HUP9903771A2 (hu) 2000-02-28
HUP9903771A3 true HUP9903771A3 (en) 2000-07-28
HU229870B1 HU229870B1 (en) 2014-10-28

Family

ID=24247176

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9903771A HU229870B1 (en) 1995-11-27 1996-11-14 Targeted cytotoxic anthracycline analogs

Country Status (27)

Country Link
US (2) US5843903A (hu)
EP (2) EP0863917B1 (hu)
JP (2) JP3987575B2 (hu)
KR (2) KR100445754B1 (hu)
CN (2) CN1166597C (hu)
AT (2) ATE251179T1 (hu)
AU (1) AU709539B2 (hu)
BR (1) BR9611647B1 (hu)
CA (2) CA2238574C (hu)
CZ (1) CZ297297B6 (hu)
DE (2) DE69630233T2 (hu)
DK (2) DK0863917T3 (hu)
EA (1) EA001372B1 (hu)
ES (2) ES2205067T3 (hu)
HK (2) HK1017363A1 (hu)
HU (1) HU229870B1 (hu)
IL (3) IL119691A (hu)
IS (2) IS2178B (hu)
MX (1) MX9804119A (hu)
NO (2) NO324035B1 (hu)
NZ (1) NZ322054A (hu)
PL (3) PL191781B1 (hu)
PT (2) PT863917E (hu)
SK (2) SK284672B6 (hu)
UA (1) UA67722C2 (hu)
WO (1) WO1997019954A1 (hu)
ZA (1) ZA969709B (hu)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6576239B1 (en) 1996-09-10 2003-06-10 The Burnham Institute Angiogenic homing molecules and conjugates derived therefrom
US6180084B1 (en) 1998-08-25 2001-01-30 The Burnham Institute NGR receptor and methods of identifying tumor homing molecules that home to angiogenic vasculature using same
GB9814527D0 (en) 1998-07-03 1998-09-02 Cyclacel Ltd Delivery system
CZ20011671A3 (cs) 1998-11-13 2001-10-17 Cyclacel Limited Peptidová nosná skupina pro transport
FR2786398B1 (fr) * 1998-11-30 2002-12-27 Synt Em Composition pharmaceutique anti-cancereuse et anti-chimioresistance comprenant un agent anticancereux et au moins un peptide
FR2786397B1 (fr) * 1998-11-30 2003-01-10 Synt Em Vecteurs peptidiques de substances a travers la barriere hematoencephalique pour etre utilises dans le diagnostic ou la therapie d'une affection du snc
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6528481B1 (en) 1999-02-16 2003-03-04 The Burnam Institute NG2/HM proteoglycan-binding peptides that home to angiogenic vasculature and related methods
US6380161B1 (en) 1999-06-21 2002-04-30 Inkine Pharmaceutical Company, Inc. Compositions for treating chemotherapy-resistant tumor cells and targeted chemotherapy compositions
WO2001036007A2 (en) * 1999-11-12 2001-05-25 Angiotech Pharmaceuticals, Inc. Compositions of a combination of radioactive therapy and cell-cycle inhibitors
ES2274823T3 (es) 1999-12-29 2007-06-01 Immunogen, Inc. Agentes cototoxicos que comprenden doxorrubicinas y daunorrubicinas y su utilizacion terapeutica.
AU4267700A (en) * 2000-01-13 2001-07-19 Academia Sinica Application of somatostatin analogs to specific delivery of anti-tumor drugs into tumor cells
US7202330B2 (en) * 2000-04-26 2007-04-10 Biosynthema Inc. RGD (Arg-Gly-Asp) coupled to (neuro)peptides
US20040170955A1 (en) 2000-09-08 2004-09-02 Wadih Arap Human and mouse targeting peptides identified by phage display
US7420030B2 (en) 2000-09-08 2008-09-02 The Board Of Regents Of The University Of Texas System Aminopeptidase A (APA) targeting peptides for the treatment of cancer
US7452964B2 (en) 2001-09-07 2008-11-18 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides against placenta and adipose tissues
KR100420007B1 (ko) * 2001-04-25 2004-03-02 노영쇠 안트라사이클린 유도체 및 이를 포함하는 항암제
WO2003028527A2 (en) 2001-09-21 2003-04-10 The Administrators Of The Tulane Educational Fund Diagnostic or therapeutic somatostatin or bombesin analog conjugates and uses thereof
EP1531846A4 (en) * 2002-02-27 2006-04-19 Us Gov Health & Human Serv CONJUGATES OF LIGAND, LINK AND CYTOTOXIC AGENS, AND RELATED COMPOSITIONS AND USE PROCESSES
US7771727B2 (en) 2002-03-01 2010-08-10 The Administrators Of The Tulane Educational Fund Conjugates of therapeutic or cytotoxic agents and biologically active peptides
US7544767B2 (en) 2002-04-05 2009-06-09 Burnham Institute For Medical Research HMGN2 peptides and related molecules that selectively home to tumor blood vessels and tumor cells
WO2003097083A1 (fr) * 2002-05-21 2003-11-27 Daiichi Suntory Pharma Co.,Ltd. Compositions medicinales contenant de la ghreline
CN100341589C (zh) 2002-05-24 2007-10-10 血管技术国际股份公司 用于涂覆医用植入物的组合物和方法
US8313760B2 (en) 2002-05-24 2012-11-20 Angiotech International Ag Compositions and methods for coating medical implants
JP2006515186A (ja) 2002-09-26 2006-05-25 アンジオテック インターナショナル アクツィエン ゲゼルシャフト 血管周囲ラップ
AU2003300076C1 (en) 2002-12-30 2010-03-04 Angiotech International Ag Drug delivery from rapid gelling polymer composition
US20040202666A1 (en) * 2003-01-24 2004-10-14 Immunomedics, Inc. Anti-cancer anthracycline drug-antibody conjugates
US20050043215A1 (en) 2003-02-19 2005-02-24 Tamara Minko Complex drug delivery composition and method for treating cancer
JP4578470B2 (ja) * 2003-04-22 2010-11-10 イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ ソマトスタチンベクター
AU2007221964B2 (en) * 2003-04-22 2008-12-11 Ipsen Pharma S.A.S. Peptide vectors
US7097993B2 (en) 2003-06-25 2006-08-29 Wisconsin Alumni Research Foundation Method for identifying an agent that modulates type 1 phosphatidylinositol phosphate kinase isoform β661 activity
WO2005086951A2 (en) * 2004-03-10 2005-09-22 Threshold Pharmaceuticals, Inc. Hypoxia-activated anti-cancer agents
US20070060534A1 (en) * 2005-06-30 2007-03-15 Threshold Pharmaceuticals, Inc. Anthracycline analogs
JP5340155B2 (ja) * 2006-09-06 2013-11-13 エテルナ ツェンタリス ゲゼルシャフト ミット ベシュレンクテル ハフツング 細胞結合分子を有するジソラゾールのコンジュゲート及びそれらの誘導体、新規ジソラゾール誘導体、それらの製法ならびに使用
EP1900742A1 (en) 2006-09-07 2008-03-19 AEterna Zentaris GmbH Conjugates of disorazoles and their derivatives with cell-binding molecules, novel disorazole derivatives, processes of manufacturing and uses thereof
US20100087370A1 (en) * 2007-02-14 2010-04-08 The General Hospital Corporation Modulation of nitric oxide signaling to normalize tumor vasculature
EP2240495B1 (en) * 2008-02-01 2015-07-15 Genentech, Inc. Nemorubicin metabolite and analog reagents, antibody-drug conjugates and methods
JP5647971B2 (ja) * 2008-04-11 2015-01-07 天津和美生物技▲術▼有限公司Ｔｉａｎｊｉｎ Ｈｅｍａｙ Ｂｉｏ−Ｔｅｃｈ Ｃｏ．Ｌｔｄ 高活性アントラサイクリン系抗生物質の誘導体、該誘導体の製造及び応用
EP2277884B1 (en) * 2008-04-11 2017-08-23 Tianjin Hemay Oncology Pharmaceutical Co., Ltd Anthracycline antibiotic derivatives with high activity, preparation methods and uses thereof
CA2727915C (en) * 2008-07-15 2016-04-26 Genentech, Inc. Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds
AU2010216372B2 (en) 2009-02-20 2013-06-20 Ipsen Pharma S.A.S. Cytotoxic conjugates having neuropeptide Y receptor binding compound
CN102050856B (zh) * 2009-11-03 2014-04-30 天津和美生物技术有限公司 具有高活性的表阿霉素的衍生物及其制备和应用
CA2818713C (en) 2010-12-02 2019-03-26 Nerviano Medical Sciences S.R.L. Process for the preparation of morpholinyl anthracycline derivatives
CN105198966B (zh) * 2014-06-26 2019-06-21 中国人民解放军军事医学科学院毒物药物研究所 GnRH类似物-细胞毒分子缀合物、其制备方法及用途
WO2016004048A2 (en) 2014-06-30 2016-01-07 Blend Therapeutics, Inc. Targeted conjugates and particles and formulations thereof
EP3045540A1 (en) 2015-01-19 2016-07-20 Æterna Zentaris GmbH Enzymatic process for the regioselective manufacturing of N-Fmoc-doxorubicin-14-O-dicarboxylic acid mono esters
WO2017075495A1 (en) 2015-10-28 2017-05-04 Tarveda Therapeutics, Inc. Sstr-targeted conjugates and particles and formulations thereof
US10450340B2 (en) 2017-02-16 2019-10-22 Monopar Therapeutics Inc. 3′-deamino-3′-(2″-pyrroline-1″-yl)-5-imino-13-deoxyanthracyclines and methods of preparation

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3725350A (en) * 1972-04-26 1973-04-03 Commercial Soluents Corp Polymeric substances comprising the reaction product of melamine, aldehyde and oxazolidines
US4299822A (en) * 1980-06-09 1981-11-10 Sidney Farber Cancer Institute, Inc. N-Trifluoroacetyladriamycin-14-O-hemiglutarate and -hemiadipate and therapeutic compositions containing same
US4464529A (en) * 1982-07-20 1984-08-07 Sri International Analogues of morpholinyl daunorubicin and morpholinyl doxorubicin
FI102355B (fi) * 1988-02-11 1998-11-30 Squibb Bristol Myers Co Menetelmä yhdistävän välikappaleen omaavien antrasykliini-immunokonjug aattien valmistamiseksi
US5217955A (en) * 1989-09-15 1993-06-08 Biomeasure, Inc. Treatment of cancer with peptide analog of bombesin, grp, litorin or neuromedin
US5304687A (en) * 1989-12-19 1994-04-19 Farmitalia Carlo Erba S.R.L. Morpholinyl derivatives of doxorubicin and process for their preparation
DE69028610T2 (de) * 1989-12-19 1997-02-06 Pharmacia Spa Chirale 1,5-diiodo-2-methoxy oder benzyloxy Zwischenprodukte
EP0450480B1 (en) * 1990-04-06 1995-06-21 The Administrators of The Tulane Educational Fund Somatostatin Analogues
ATE127476T1 (de) * 1990-04-06 1995-09-15 Univ Tulane Lhrh-analoge.
JP3169425B2 (ja) * 1992-03-27 2001-05-28 三共株式会社 アジドペンタンサイクリトール
US6214345B1 (en) * 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates

Also Published As

Publication number Publication date
CN1166597C (zh) 2004-09-15
ES2310222T3 (es) 2009-01-01
SK284392B6 (sk) 2005-03-04
EA199800492A1 (ru) 1998-12-24
EP1384710B1 (en) 2008-07-16
HK1052920B (zh) 2005-03-04
ATE251179T1 (de) 2003-10-15
PL188786B1 (pl) 2005-04-29
IS2634B (is) 2010-06-15
WO1997019954A1 (en) 1997-06-05
NO982252L (no) 1998-05-15
CA2238574C (en) 2004-10-19
HUP9903771A2 (hu) 2000-02-28
DE69630233T2 (de) 2004-08-05
EA001372B1 (ru) 2001-02-26
AU709539B2 (en) 1999-09-02
IL119691A0 (en) 1997-02-18
JP3987575B2 (ja) 2007-10-10
BR9611647B1 (pt) 2010-03-09
HK1052920A1 (en) 2003-10-03
KR100445754B1 (ko) 2004-12-08
SK284672B6 (sk) 2005-08-04
HU229870B1 (en) 2014-10-28
BR9611647A (pt) 1999-02-23
CZ135798A3 (cs) 1998-10-14
IL134685A (en) 2002-12-01
AU7572296A (en) 1997-06-19
PT863917E (pt) 2004-02-27
NO982252D0 (no) 1998-05-15
EP1384710A1 (en) 2004-01-28
JP2000502055A (ja) 2000-02-22
PL191781B1 (pl) 2006-07-31
SK62898A3 (en) 1999-06-11
NZ322054A (en) 1999-04-29
ES2205067T3 (es) 2004-05-01
IL119691A (en) 2002-02-10
CN1137136C (zh) 2004-02-04
JP2007045845A (ja) 2007-02-22
NO20051111L (no) 2005-03-01
EP0863917A1 (en) 1998-09-16
DE69637604D1 (de) 2008-08-28
PT1384710E (pt) 2008-10-08
CA2471775A1 (en) 1997-06-05
IS4734A (is) 1998-05-05
US5843903A (en) 1998-12-01
PL326865A1 (en) 1998-10-26
DK1384710T3 (da) 2008-11-17
KR100467899B1 (ko) 2005-01-24
MX9804119A (es) 1998-09-30
ZA969709B (en) 1997-08-25
EP0863917B1 (en) 2003-10-01
IL134685A0 (en) 2001-04-30
PL187230B1 (pl) 2004-06-30
UA67722C2 (en) 2004-07-15
US6184374B1 (en) 2001-02-06
DK0863917T3 (da) 2004-01-19
IS8567A (is) 2006-11-09
CA2471775C (en) 2008-01-29
HK1017363A1 (en) 1999-11-19
DE69630233D1 (de) 2003-11-06
IS2178B (is) 2006-12-15
CZ297297B6 (cs) 2006-11-15
KR19990071672A (ko) 1999-09-27
ATE401305T1 (de) 2008-08-15
CA2238574A1 (en) 1997-06-05
KR20040037176A (ko) 2004-05-04
CN1202903A (zh) 1998-12-23
NO324035B1 (no) 2007-07-30
JP4778405B2 (ja) 2011-09-21
CN1405127A (zh) 2003-03-26

Similar Documents

Publication Publication Date Title
HUP9903771A3 (en) Targeted cytotoxic anthracycline analogs
EP0808093A4 (en) PLANTATION DEVICE
HK1008489A1 (en) Lactacystin analogs
PL322496A1 (en) Plug-in multiplexer
EP0831817A4 (en) CONJUGATES TARGETED ON ANTI-PROCESSING CELLS
GB9511366D0 (en) Novel formulations
AP9901465A0 (en) Illudin analogs useful as antitumor agents
GB9503400D0 (en) Therpeutic agents
ZA964129B (en) N-acyl-2-aryl cyclopropylmethylamine derivatives as melatonerigics
GB2296495B (en) Anthracycline derivatives
GB2302809B (en) Antitumor agent
EP0868430A4 (en) THERAPEUTIC COMPOSITIONS
GB9609203D0 (en) Formulations
GB9513382D0 (en) Planters
PL57347Y1 (en) Power-lift-mounted deep-tillage plough
GB9509493D0 (en) Multi-share plough
HU791U (en) Plough
KR0111967Y1 (en) Seeder
CA75600S (en) Planter
GB9510349D0 (en) Formulations
GB9508144D0 (en) Formulations
GB9509941D0 (en) Formulations
GB9506641D0 (en) Targeting agents (single chain NDP-ALPHA-MSH)
HU9501541D0 (en) Cultivator
PL55685Y1 (en) Small-field plough